Trevi Therapeutics Inc Dossier - Source-backed chat

Trevi Therapeutics Inc

TRVINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.04

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $14.32Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2B

Enterprise Value $2B

Shares Outstanding 161.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Trevi Therapeutics is a clinical-stage biopharmaceutical company uniquely positioned to address significant unmet needs in chronic cough indications, particularly chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The company's lead candidate, Haduvio (oral nalbuphine extended-release), is the first and only investigational therapy to demonstrate statistically significant reductions in cough frequency across both IPF-related chronic cough and RCC in clinical trials. Following a highly successful End-of-Phase 2 meeting with the FDA, Trevi has aligned on a clear regulatory pathway and is initiating parallel Phase 3 trials in IPF-related chronic cough. Crucially, a major follow-on equity offering in April 2026 raised approximately $162 million in net proceeds, extending the company's cash runway into 2030. This robust balance sheet fully funds the late-stage clinical development of Haduvio through potential FDA approval, significantly de-risking the investment profile and providing a compelling entry point for investors ahead of major clinical readouts starting in 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$23.00

Mean target$28.18

High · most bullish analyst$40.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

In the bear case, one or both of the Phase 3 trials in IPF-related chronic cough fail to meet their primary endpoints of objective cough frequency reduction, or reveal unexpected safety concerns (such as adverse events related to the opioid receptor mechanism). Additionally, enrollment delays in the RCC or non-IPF ILD trials could accelerate cash burn, forcing the company to seek dilutive financing or restructure its pipeline. Failure of the lead candidate Haduvio would severely impair the company's valuation, as its pipeline is highly concentrated on this single asset.

Base CaseCentral scenario

In the base case, Trevi successfully initiates and executes its parallel Phase 3 trials in IPF-related chronic cough and its Phase 2b trials in RCC and non-IPF ILD. The company maintains a disciplined cash burn rate, preserving its runway into 2030. Topline data from the first Phase 3 trial is delivered in the second half of 2027, and the second Phase 3 trial reads out in the first half of 2028, both demonstrating positive efficacy and safety profiles consistent with Phase 2 results. This leads to a successful NDA submission and subsequent FDA approval of Haduvio for IPF-related chronic cough, establishing Trevi as the market leader in a multi-billion dollar indication with no currently approved therapies.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Haduvio is the first investigational therapy to show statistically significant cough reduction in both IPF-related chronic cough and RCC.
Strong cash position of $171.8 million at Q1 2026, bolstered by an additional $162 million in net proceeds from an April 2026 equity offering, extending the cash runway into 2030.
Clear regulatory pathway established with the FDA following a productive End-of-Phase 2 meeting in Q1 2026.
Parallel Phase 3 trials in IPF-related chronic cough are fully funded through potential FDA approval.

Key Investment Risks

High asset concentration risk, as the company's valuation is almost entirely dependent on the clinical and regulatory success of Haduvio.
Clinical trial execution risks, including potential delays in patient enrollment across multiple parallel late-stage studies.
Regulatory risks inherent in clinical-stage biotechnology, where the FDA may require additional studies or refuse approval despite positive trial data.
Potential side effects or tolerability issues associated with Haduvio's mechanism of action as a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist.

Thesis Invalidation Triggers

Failure of the first Phase 3 trial in IPF-related chronic cough to meet its primary endpoint of objective cough frequency reduction.
Safety signals or serious adverse events emerging during the Phase 3 trials that lead to a clinical hold by the FDA.
Significant delays in clinical trial timelines that push back expected readouts beyond 2028, leading to an accelerated cash burn rate.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.